Archives

2 March 2022 ASX ANNOUNCEMENT Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial Medical Developments International Ltd (ASX: MVP) announces that the US Food and Drug Administration (FDA) has unconditionally lifted the agency’s clinical hold on Penthrox.  This means that MVP can immediately begin preparing for its Phase III US […]

25 February 2022 ASX announcement Please refer to the following link for the MVP FY22 Half Year Results Investor Presentation slides – MVP FY22 HY Investor Presentation

24 February 2022 ASX Announcement Medical Developments International Limited (ASX:MVP) today released its FY22 Half Year Report and Accounts. Please refer to the following link for a copy of the announcement – MVP FY22 Half Year Report and Accounts 

28 October 2021 ASX ANNOUNCEMENT Company Chair and CEO’s Address to Shareholders On Thursday 28 October 2021, MVP held its 18th Annual General Meeting.  The Company Chair and CEO address to shareholders is outlined in the following attachment – ASX Announcement – Address to Shareholders

27 September 2021 FY21 Annual Report and Annual General Meeting Notice of Meeting Medical Developments International (MVP) has released its FY21 Annual Report and also its AGM Notice of Meeting. Both can be found via the following links: MVP FY21 Annual Report Notice of AGM and Proxy Form

25 August 20201 ASX Announcement Medical Developments International Limited (ASX: MVP) today released its FY21 Preliminary Final Report and Full Year Accounts. Please refer to the following link for a copy of the announcement – MVP FY21 Preliminary Final Report

16 July 2021 ASX ANNOUNCEMENT MVP Announces Outcome of Balance Sheet Review Medical Developments International Ltd (ASX: MVP) today announced that following its annual asset impairment review, it expects to recognise a non-cash charge of $7.5 – 8.5 million (after tax) within the Group’s 30 June 2021 accounts. MVP’s respiratory business has been adversely impacted […]

5 March 2021 ASX ANNOUNCEMENT Appointment of Non-Executive Director – Mary Sontrop Medical Developments International Limited (ASX: MVP) is pleased to announce the appointment of Ms. Mary Sontrop as a Non-Executive Director of the Company with immediate effect. Mary has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration.  During […]

26 February 2021 ASX ANNOUNCEMENT Medical Developments International Limited (ASX:MVP) has today released its FY21 Half Year Report and Accounts. Please click on the following link to view the release – FY21 HY Report and Accounts  

14 December 2020 ASX ANNOUNCEMENT Medical Developments completes a A$25 million placement to accelerate the commercialisation of Penthrox in European Markets Please refer to the attached for the full announcements – MVP – ASX Announcement – Completion of Placement Please also refer to the related Investor Presentation – MVP Investor Presentation